20 Oct Morphiex’s CD47 Inhibitor in Combination with Ipilimumab Enhances Survival in Melanoma
Check out our new publication in the Journal of Immunology & Immunotherapy demonstrating the synergy of Morphiex’s CD47 inhibitor (MBT-001) with ipilimumab (CTLA4) and CAR-T.
MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). MBT-001 is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. In addition, Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001.